GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
2.940
-0.070 (-2.33%)
At close: Oct 31, 2024, 4:00 PM
2.820
-0.120 (-4.08%)
After-hours: Oct 31, 2024, 6:13 PM EDT
GT Biopharma Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for GT Biopharma.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for GT Biopharma.
Recommendation Trends
Rating | Mar '23 | Apr '23 | May '23 | Jun '23 | Jul '23 | Aug '23 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +5,002.04% | Aug 8, 2023 |
EF Hutton | EF Hutton | Hold Reiterates $60 | Hold | Reiterates | $60 | +1,940.82% | Aug 7, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +5,002.04% | Jun 5, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +5,002.04% | May 17, 2023 |
EF Hutton | EF Hutton | Hold Reiterates $60 | Hold | Reiterates | $60 | +1,940.82% | May 16, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-11.02
from -5.64
EPS Next Year
-0.72
from -11.02
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | n/a | n/a |
Avg | n/a | n/a |
Low | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -11.34 | -0.75 |
Avg | -11.02 | -0.72 |
Low | -10.58 | -0.70 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.